vs
Side-by-side financial comparison of Opus Genetics, Inc. (IRD) and Onfolio Holdings, Inc (ONFO). Click either name above to swap in a different company.
Opus Genetics, Inc. is the larger business by last-quarter revenue ($3.9M vs $2.0M, roughly 1.9× Onfolio Holdings, Inc). On growth, Opus Genetics, Inc. posted the faster year-over-year revenue change (-10.2% vs -20.1%). Over the past eight quarters, Opus Genetics, Inc.'s revenue compounded faster (50.3% CAGR vs 13.0%).
Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.
Onfolio Holdings Inc. acquires, manages and grows a diversified portfolio of small to medium-sized online businesses, including niche content sites, e-commerce stores, and SaaS tools. It operates primarily in North America and Western Europe, focusing on high-margin, sustainable digital assets with stable revenue streams.
IRD vs ONFO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $2.0M |
| Net Profit | — | $-547.1K |
| Gross Margin | — | 50.0% |
| Operating Margin | — | -59.1% |
| Net Margin | — | -27.0% |
| Revenue YoY | -10.2% | -20.1% |
| Net Profit YoY | 53.0% | -69.0% |
| EPS (diluted) | — | $-0.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $2.0M | ||
| Q3 25 | $3.1M | $2.7M | ||
| Q2 25 | $2.9M | $3.1M | ||
| Q1 25 | $4.4M | $2.8M | ||
| Q4 24 | $4.3M | $2.5M | ||
| Q3 24 | $3.9M | $2.0M | ||
| Q2 24 | $1.1M | $1.7M | ||
| Q1 24 | $1.7M | $1.6M |
| Q4 25 | — | $-547.1K | ||
| Q3 25 | $-17.5M | $-700.7K | ||
| Q2 25 | $-7.4M | $-534.4K | ||
| Q1 25 | $-8.2M | $-806.4K | ||
| Q4 24 | — | $-323.8K | ||
| Q3 24 | $-7.5M | $-335.6K | ||
| Q2 24 | $-7.8M | $-629.0K | ||
| Q1 24 | $-7.1M | $-477.8K |
| Q4 25 | — | 50.0% | ||
| Q3 25 | — | 64.6% | ||
| Q2 25 | — | 61.6% | ||
| Q1 25 | — | 60.7% | ||
| Q4 24 | — | 53.6% | ||
| Q3 24 | — | 59.9% | ||
| Q2 24 | — | 56.5% | ||
| Q1 24 | — | 63.3% |
| Q4 25 | — | -59.1% | ||
| Q3 25 | -269.9% | -9.8% | ||
| Q2 25 | -309.0% | -16.1% | ||
| Q1 25 | -227.2% | -27.9% | ||
| Q4 24 | — | -43.9% | ||
| Q3 24 | -207.1% | -16.5% | ||
| Q2 24 | -748.9% | -35.1% | ||
| Q1 24 | -450.5% | -28.7% |
| Q4 25 | — | -27.0% | ||
| Q3 25 | -566.9% | -25.6% | ||
| Q2 25 | -257.5% | -17.0% | ||
| Q1 25 | -187.5% | -28.7% | ||
| Q4 24 | — | -12.8% | ||
| Q3 24 | -194.6% | -16.7% | ||
| Q2 24 | -698.3% | -36.4% | ||
| Q1 24 | -415.3% | -30.1% |
| Q4 25 | — | $-0.37 | ||
| Q3 25 | $-0.25 | $-0.16 | ||
| Q2 25 | $-0.12 | $0.13 | ||
| Q1 25 | $-0.24 | $-0.18 | ||
| Q4 24 | — | $-0.36 | ||
| Q3 24 | $-0.29 | $-0.08 | ||
| Q2 24 | $-0.30 | $0.14 | ||
| Q1 24 | $-0.29 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $45.1M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $15.3M | $2.5M |
| Total Assets | $50.2M | $11.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.1M | — | ||
| Q3 25 | $30.8M | — | ||
| Q2 25 | $32.4M | — | ||
| Q1 25 | $41.8M | — | ||
| Q4 24 | $30.3M | — | ||
| Q3 24 | $36.6M | — | ||
| Q2 24 | $41.4M | — | ||
| Q1 24 | $47.2M | $529.8K |
| Q4 25 | $15.3M | $2.5M | ||
| Q3 25 | $6.0M | $2.2M | ||
| Q2 25 | $17.5M | $3.1M | ||
| Q1 25 | $5.1M | $3.6M | ||
| Q4 24 | $6.7M | $3.3M | ||
| Q3 24 | $34.3M | $3.9M | ||
| Q2 24 | $40.6M | $4.5M | ||
| Q1 24 | $46.1M | $5.2M |
| Q4 25 | $50.2M | $11.4M | ||
| Q3 25 | $36.1M | $8.3M | ||
| Q2 25 | $38.7M | $8.8M | ||
| Q1 25 | $48.2M | $9.4M | ||
| Q4 24 | $36.9M | $9.6M | ||
| Q3 24 | $40.4M | $8.6M | ||
| Q2 24 | $44.8M | $8.9M | ||
| Q1 24 | $51.8M | $8.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-35.3M | $-397.3K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-35.3M | $-397.3K | ||
| Q3 25 | $-6.2M | $34.2K | ||
| Q2 25 | $-10.3M | $-430.1K | ||
| Q1 25 | $-9.0M | $-145.0K | ||
| Q4 24 | $-25.6M | $-471.6K | ||
| Q3 24 | $-5.1M | $67.0K | ||
| Q2 24 | $-7.3M | $-332.7K | ||
| Q1 24 | $-5.7M | $-431.0K |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IRD
Segment breakdown not available.
ONFO
| B Two B | $1.6M | 81% |
| B Two C | $243.0K | 12% |
| Other | $138.6K | 7% |
